Literature DB >> 26370697

Can we prevent type 1 diabetes?

Giovanna Beauchamp1, Michael J Haller2.   

Abstract

Type 1 diabetes (T1D) affects 1.93 in 1000 youth in the USA. Over the last 40 years, a combination of genetic and immunological markers has been developed allowing for the accurate prediction of progression to T1D. Despite our abilities to predict disease and the marked improvement in our understanding of the natural history of T1D, therapies capable of preventing or reversing T1D remain elusive. This article will review recent and ongoing efforts to understand the causes of T1D and related efforts to study potential therapies aimed at preventing T1D.

Entities:  

Keywords:  Antigen-specific therapy; Natural history; Non-antigen-specific therapy; Prevention; Type 1 diabetes

Mesh：

Substances：

Year:  2015        PMID： 26370697     DOI： 10.1007/s11892-015-0658-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  35 in total

1.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Infant exposures and development of type 1 diabetes mellitus: The Diabetes Autoimmunity Study in the Young (DAISY).

Authors:  Brittni Frederiksen; Miranda Kroehl; Molly M Lamb; Jennifer Seifert; Katherine Barriga; George S Eisenbarth; Marian Rewers; Jill M Norris
Journal:  JAMA Pediatr       Date:  2013-09       Impact factor: 16.193

3.  Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.

Authors:  A G Ziegler; M Hummel; M Schenker; E Bonifacio
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

4.  Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes.

Authors:  H Peter Chase; David Boulware; Henry Rodriguez; David Donaldson; Sonia Chritton; Lisa Rafkin-Mervis; Jeffrey Krischer; Jay S Skyler; Michael Clare-Salzler
Journal:  Pediatr Diabetes       Date:  2014-07-12       Impact factor: 4.866

5.  Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents.

Authors:  Michael Hummel; Ezio Bonifacio; Sandra Schmid; Markus Walter; Annette Knopff; Anette-G Ziegler
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

6.  Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study.

Authors:  Cecilia Andersson; Annelie Carlsson; Corrado Cilio; Elisabeth Cedervall; Sten-Anders Ivarsson; Berglind Jonsdottir; Björn Jönsson; Karin Larsson; Jan Neiderud; Ake Lernmark; Helena Elding Larsson
Journal:  Pediatr Diabetes       Date:  2013-03-08       Impact factor: 4.866

7.  Development of autoantibodies in the TrialNet Natural History Study.

Authors:  Kendra Vehik; Craig A Beam; Jeffrey L Mahon; Desmond A Schatz; Michael J Haller; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer
Journal:  Diabetes Care       Date:  2011-07-12       Impact factor: 19.112

8.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

9.  Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.

Authors:  H K Genant; C G Peterfy; R Westhovens; J-C Becker; R Aranda; G Vratsanos; J Teng; J M Kremer
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103

10.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307
View more
  2 in total

1.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

2.  Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation.

Authors:  Huashan Gao; Qian Zhao; Shanshan Tang; Kaiying Li; Fujian Qin; Ziwei Song; Yi Pan; Liang Jin; Yanfeng Zhang
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.